cyrilzakka/clinical-trials huggingface dataset:
Video Messages for Smoking Cessation Campaign

240 adult smokers will be recruited. Subjects will be asked to view video messages that encourage smoking cessation. The effect of these videos will be assessed.

This study will use a parallel, two-arm randomized control trial design. After consenting to participate in the study, Participants will be invited to fill out the online questionnaire form which will include one randomly selected ad exposure. The participation in the study will contain three parts: pre-test, video-ad stimuli, and post-test. Pretest will contain questions on the demographic information and readiness to quit smoking. Video ad stimuli segment will contain the selected video ad. The posttest will contain the manipulation check, readiness to quit smoking, message engagement, and PME questions. A randomization table will be generated using Research Randomizer software (ResearchRandomizer.org; Social Psychology Network) and subjects will be randomized to video ad 1 or video ad 2 in permuted blocks of 2.

The video ads are a part of the "Victory" media campaign designed for the tobacco cessation clinical project in Mongolia. Each video ad ends with the slogan "Every attempt is a victory".

Video Ad 1. This video ad was designed using a loss-framed message and emphasized the costs of continuing to smoke (losses) demonstrating the severe negative health consequences of smoking (e.g., complicated COVID-19, ICU hospitalization). The main actor in the ad is a famous young male Mongolian singer.

Video Ad 2. The video emphasized the benefits of quitting (gains) using a female actor.

After the viewing of the video ad participants will be asked to report reaction by completing an online posttest survey.

Eligibility Criteria:
Inclusion Criteria:

* Eighteen years and older
* Current smoker every day or some days
* Has smoked a minimum of 100 cigarettes in a lifetime

Exclusion Criteria:

* Non Smokers
* Must have internet access to complete questionnaires
Transthyretin Cardiac Amyloidosis in Patients With Idiopathic Carpal Tunnel Syndrome Referred for Release Surgery

This study will determine the prevalence of transthyretin amyloidosis in pathology of the transverse carpal ligament and cardiac involvement using natriuretic peptides, electrocardiography and echocardiography in patients referred for carpal tunnel release surgery of idiopathic carpal tunnel syndrome. This study will describe the relationship between amyloid deposition observed on the transverse carpal ligament and the presence of cardiac involvement.

Unrecognized wild-type transthyretin amyloidosis (ATTRwt) in patients with idiopathic carpal tunnel syndrome (CTS) is a prevalent aging-related disorder. Amyloid deposition in the tenosynovial tissue has been reported in \~35% of patients with idiopathic carpal tunnel syndrome.

Otherwise, CTS has been shown to be the most common initial symptom of systemic wild-type transthyretin amyloidosis. The clinical significance of subclinical ATTRwt deposits in the heart in elderly patients has yet to be determined, but these deposits could contribute to the development of heart failure with preserved ejection fraction. ATTRwt has been reported in \~15% of patients with heart failure with preserved ejection fraction. Early detection of amyloid deposition in the transverse carpal ligament of patients with CTS could anticipate cardiac damage and progression to heart failure.The aim of this study is to determine the prevalence of transthyretin amyloidosis in pathology of the transverse carpal ligament and cardiac involvement using natriuretic peptides, electrocardiography and echocardiography in patients referred for carpal tunnel release surgery of idiopathic carpal tunnel syndrome.

Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 year-old
* Indication carpal tunnel release surgery of idiopathic carpal tunnel syndrome.
* To agree to participate (signature of the informed consent)
* Affiliate or beneficiary of a social security scheme

Exclusion Criteria:

* Patients with non-idiopathic carpal tunnel syndrome with medical contraindication : pregnancy, obesity (body mass index \> 30), diabetes, rheumatoid arthritis, sarcoidosis, purulent tenosynovitis, tuberculosis, systemic lupus erythematosus, hypothyroidism or hyperthyroidism and gout.
* Patients with history of cardiac disease or coronary artery disease.
* Patients with systemic amyloidosis already known.
* Patients unde guardianship or curatorship
Observational Study of Osseotite Certain Tapered Implants in Immediate Loading Cases

Osseotite Certain Tapered implants placed in immediate prosthesis loaded cases.

Osseotite Certain Tapered implants are placed and restored immediately (during the same visit)

Eligibility Criteria:
Inclusion Criteria:

* patients of either sex and older than 18 years of age
* patients needing at least one dental implant to treat partial edentulism
* patients physically able to tolerate surgical and restorative dental procedures
* patients agreeing to all protocol visits

Exclusion Criteria:

* patients with infection or severe inflammation at the intended treatment sites
* patients smoking greater than 10 cigarettes per day
* patients with uncontrolled diabetes mellitus
* patients with uncontrolled metabolic diseases
* patients who received radiation treatment to the head in the past 12 months
* patients needing bone grafting at the intended treatment sites
* patients known to be pregnant at screening visit
* patients with para-functional habits like bruxing and clenching
A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)

This study will assess the safety and tolerability of single doses of odanacatib (MK0822) when administered with a light breakfast.


Eligibility Criteria:
Inclusion Criteria:

* Subject is male and between the ages of 18 and 45
* Subject is within 25% of ideal body weight and weighs between 55 and 95 kg
* Subject is in generally good health
* Subject is a nonsmoker

Exclusion Criteria:

* Subject has multiple or severe allergies to food or medications
* Subject has a history of metabolic bone disease, kidney/bladder stones, or treatment with bisphosphonates
* Subject has any infections, including HIV
* Subject has donated blood or taken another investigational drug in the last month
* Subject consumes excessive amounts of caffeine or alcohol
* Subject has a history of any illness that may confound the results of the study or pose additional risk in administering the study drug
Temporal Patterns of Diet and the Changes in Body Composition and Blood Pressure

The study includes two parts: 1) an observational study examines the association of meal frequency, meal timing, and meal regularity with short-term changes in blood pressure and body composition; 2) a randomized controlled intervention examines the influence of recommendation of increase breakfast frequency and decrease nighttime snacking on 1-year changes in blood pressure and body composition.


Eligibility Criteria:
Inclusion criteria:

* Adult
* Willing to participate

Exclusion criteria:

* Being pregnant
* hemodialysis patients
* clinical diagnosis of cardiovascular diseases
* clinical diagnosis of cancer
* clinical diagnosis of dementia
* clinical diagnosis of eating disorders
* having metal orthopedic implants
* having pacemaker implanted
Academic Stress and Proinflammatory Cytokines: Omega-3 Intervention

This study is designed to examine the effects of fish oil on immune function and mood in medical students.

This study will examine how supplementation with omega-3 polyunsaturated fatty acids (key fish oil components) affects immune and mood responses to examination stress. This study will examine these outcomes in medical students during academic examination periods as well as less stressful non-exam periods. Participants will take fish oil supplements or placebo pills for approximately 3 months during which time relevant mood, endocrine, and immune measures will be assessed.

For detailed information about the study, please visit our website at http://www.stressandhealth.org

Eligibility Criteria:
Inclusion Criteria:

* OSU preclinical medical or dental student, or graduate nursing student
* male or female

Exclusion Criteria:

* taking certain medications with immune or endocrine effects
* chronic health conditions
* smoking
* excessive use of alcohol or caffeine
* significant digestive problems
* routine use of fish oil or flaxseed supplements or high fish intake
* fish allergy
The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

Heavy marijuana users report experiencing trouble sleeping when they try to quit, but this has not been carefully studied. This research is being done to learn more about sleep function in heavy marijuana users, and to determine whether a medication approved for treating insomnia can help restore normal sleep function during brief periods of abstinence.


Eligibility Criteria:
Inclusion Criteria:

* current use of marijuana
* able to give informed consent

Exclusion Criteria:

* dependence on drug other than marijuana
* current sleep disorder
* pregnant, breast feeding, or planning to become pregnant within the next 3 months
* currently seeking treatment for cannabis-related problems or otherwise trying to reduce use
* use of cannabis under the guidance of a physician for a medical disorder
* unstable or uncontrolled cardiovascular disease (e.g., hypertension, angina)
* allergy to study medication
Amlodipine as add-on to Olmesartan in Hypertension

Test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with olmesartan alone.


Eligibility Criteria:
Inclusion Criteria:

* Mean sitting BP of greater than or equal to 140/90-115 mmHg and mean 24h dBP greater than or equal to 80 mmHg with at least 30% of daytime readings greater than 85 mmHg prior to randomization.

Exclusion Criteria:

* Secondary hypertension of any aetiology;
* Any serious disorders which may limit the ability to evaluate the efficacy or safety of the test drug(s);
* History of myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, congestive heart failure, hypertensive encephalopathy, stroke or TIA within the last 6 months.
Molecular Tumor Board at the Center for Personalized Medicine Tübingen

Molecular Tumor Board at the Center for Personalized Medicine

Molecular Tumor Board at the Center for Personalized Medicine The study objectives are

* To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care
* To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)
* To prospectively assess patient-reported outcome of MTB patients
* To evaluate compliance to MTB suggestions in routine clinical care

Eligibility Criteria:
Inclusion Criteria:

* Given informed consent ("broad consent" of the University Hospital Tübingen)
* ≥ 18 years of age
* Clinical indication for a referral to Molecular Tumor Board by the treating physician

Exclusion Criteria:

* The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients
Return to Sports After ACLR

Patients who were surgically treated with ACL reconstruction at a single clinic between 2013 and 2018 will be approached by a questionnaire regarding their return to sport after surgery. Questions will focus on the timepoint of the return, subsequent injuries, and the impact of the initial injury on the life of the patients. In addition, existing clinical data from the baseline visit and from the follow-up visits offered routinely to the patient will be used.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18
* ACL injury
* surgically treated with ACL reconstruction at the crossklinik or affiliated institutions between 1.1.2013 and 31.12.2018

Exclusion Criteria:

* different treatment approach to the injury (e.g. conservative, stimulation of healing response, surgical treatment for re-rupture etc.).
Retrospective Survey Evaluating the Effectiveness and Safety of Dual Inhibition Lipid-lowering in the Treatment of Dyslipidemia (Study P05171)(COMPLETED)

This retrospective study evaluates the effectiveness and safety of ezetimibe plus statin or ezetimibe plus fenofibrate in dyslipidemic patients that were treated with these dual inhibition lipid lowering regimens as part of their normal standard of care. This study assesses the percentage of patients who achieve LDL-C target goals and also evaluates the patient compliance to treatment.

Retrospective medical chart review

Eligibility Criteria:
Inclusion Criteria:

* Patient was \> 20 years and \< 75 years of age on the index date\*
* Patient diagnosed with dyslipidemia who did not respond adequately based on NCEP ATP III target to previous lipid lowering treatment, and have received dual inhibition therapy, such as ezetimibe plus statins, ezetimibe plus fenofibrate or ezetimibe alone, for at least 3 months
* Patient has at least one Total Cholesterol and LDL-C measurements at baseline and 3 months after initiating the dual inhibition therapy.
* Patient has the following records documented in the chart during the data collection period:

  * Medical history and co morbidities (if available)
  * Total Cholesterol and LDL-C. test results before and after initiating the dual inhibition therapy
  * Prescription information of lipid-lowering dual inhibition regimens NOTE: \* Index date: the date of initiating dual inhibition therapy

Exclusion Criteria:

* Patients who do not meet all the inclusion criteria will be excluded from this survey.
* Patients who were enrolled in other clinical trial observing specific study procedures which deviates from normal practice will not be included in this study.
Study of Factors and Mechanisms Influencing the Effects of Treatments in Crohn's Disease

The course of Crohn's disease (CD) varies considerably between patients, but reliable prognostic markers are not available in clinical practice. Even though several parameters have been associated with prognosis in CD-including clinical features, serology and genetic variants-none are sufficient to guide therapy in clinical practice. Trying to find out the mechanisms influencing the effectiveness of treatments and develop a personalized therapy is an urgent problem in the era of biologics as the investigators now have a growing armamentarium of IBD therapies. Several scientists found that the levels of T cells subsets ratio and inflammation cytokines were significantly increased in the intestinal mucosa and serum in active IBD patients, whereas mucosal innate lymph cells had specific effects in inflammation. However the studies about the differences of lymph cell levels between subgroups of IBD patients and their relationships with effectiveness of treatments are relatively rare. Based on above, the investigators plan to recruit patients diagnosed and suspicious of Crohn's disease and a group of diseases in differential diagnosis of CD to keep track of their disease characteristics, therapy and response, collect their blood sample at specific points of time, to investigate the mechanisms of heterogeneity of therapy effectiveness.


Eligibility Criteria:
Inclusion Criteria:

* Newly diagnosed or Previously diagnosed of Crohn's disease according to 2010 WGO criteria for Crohn's disease
* Aged 14-80 years old.

Exclusion Criteria:

* History of malignancy
* Pregnant/breastfeeding at screening
* Other serious medical or psychiatric illness.
* Unable to comply with protocol requirements
Quality of Dying in the Intensive Care Unit: Validation of the CAESAR Scale

The purpose of the study is to evaluate the quality of the dying process in french ICUs (assessed by the CAESAR scale) and to compare physicians', nurses' and relatives perceptions and experiences, with a one-year follow-up of bereaved relatives.

Our hypothesis is that perception of the quality of dying may impact on relatives' experience of bereavement (anxiety, depression, complicated grief, posttraumatic stress disorder (PTSD)).

Seventy percent of all deaths occur in the hospital environment, and amongst them 20% occur in intensive care units (ICU). In France, no studies have evaluated the quality of the end-of-life process from both the professional and the lay perspective.

The CAESAR scale has been developed from literature reviews and qualitative interviews with relatives, physicians and nurse to assess quality of dying in ICU. Our hypothesis is that perception of the quality of dying may impact on relatives' experience of bereavement (anxiety, depression, complicated grief, PTSD).

Eligibility Criteria:
Inclusion Criteria:

* Adult patients Deceased in the ICU after at least 48 hours of ICU stay
* At least one visit of a relative in the ICU

Exclusion Criteria:

* no French-speaking relative
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

This is a pilot, phase 2, prospective, comparative study to evaluate the safety and efficacy of the combination of Levulan® Kerastick® for Topical Solution and blue light illumination using the BLU-U® Blue Light Photodynamic Therapy Illuminator (LevulanPDT).

The study hypothesis is that post solid organ transplantation patients, highly susceptible to non-melanoma skin cancer, can be treated safely and effectively through clinical cyclic application of PDT, lessening morbidity and possible mortality for this immunosuppressed patient population.


Eligibility Criteria:
Inclusion Criteria:

* Received solid organ transplant
* 3-24 months post-transplant (any number of transplant)
* Time interval of at least 6 days duration where complications such as rejection episodes, viral infections, surgical interventions and therapies with mono or polyclonal antibodies are ruled out by the transplant team.
* No prior history of NMSC in the treatment fields
* No AK/Bowen's disease in the treatment fields within the last 3 months.
* Moderate to severe sun damage
* Be willing to forego other interventions in the treatment fields than the ones approved by the investigator that would interfere with the protocol or evaluation of the study medication

Exclusion Criteria:

* Patients with Fitzpatrick's scale skin type IV-VI
* Cutaneous photosensitivity to wavelengths of 400-450 nm, porphyria or known allergies to porphyrins
* Known sensitivity to any of the components of the Levulan® Kerastick® for Topical Solution
* Prior use of topical or systemic therapies that might interfere with the evaluation of the study medication during the study, within a 3 month washout period from the time of the screening visit
* Unable to return for follow-up visits and tests
* Any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study
Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric

The primary goal of the study is to compare the success rates of pulpal anesthesia (defined as ability to complete the intended dental procedure without the need for rescue anesthesia) between Kovanaze nasal mist and Articaine needle anesthesia.

In June 2016, an intranasal delivery system of local anesthesia called Kovanaze, gained FDA approval. \[9\] Kovanaze is available as a 0.2 ml metered spray and is intended to achieve pulpal anesthesia of 5 maxillary teeth on either side of the face. Even though success rates between 83 and 90 % have been reported for adults and children \>40kg, \[10\] FDA label (Section 14.2) provides data for children (\>10 kg) indicating that the drug is safe for use in children as long as the dose is adjusted to bodyweight of the child. \[9\]

* One 0.1 mL spray for patients weighing 10 kg to less than 20 kg;
* Two 0.1 mL sprays for 20 kg to less than 40 kg; or
* Two 0.2 mL sprays for patients weighing 40 kg or more.

With the ability to avoid the traditional painful injection Kovanaze offers promise in the field of maxillary anesthesia and this study intends to:

1. Compare Kovanaze to conventional needle anesthetic children (at least 6 years of age and weighing \> 20 kg)
2. Evaluate patient anxiety, tolerance and acceptability of Kovanaze in patients undergoing dental procedures

Eligibility Criteria:
Inclusion Criteria:

* American Society of Anesthesiologists Class I or II
* Preoperative heart rate of 55 to 100 beats per minute
* Maximum blood pressure reading of 166/100 mmHg
* Treatment for a pathology in the maxillary anterior tooth or premolar that requires administering local anesthesia

Additional Pediatric Inclusion Criteria:

* Children \>20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth

Additional Endodontic Inclusion Criteria:

* Adults (\>18 years) who require non-surgical root canal treatment in maxillary anterior teeth

Additional General Practice Inclusion Criteria:

* Adults who require restorations in the maxillary teeth that would need local anesthesia

Exclusion Criteria:

* Inadequately controlled thyroid disease
* Five or more nosebleeds in the past month
* Known allergy to any study drug or para-aminobenzoic acid
* History of methemoglobinemia
* Taking monoamine oxidase inhibitors, tricyclic antidepressants (i.e. amitriptyline), or non-selective beta adrenergic antagonists (i.e. propranolol);
* Taking oxymetazoline-containing products (i.e., Afrin) in the last 24 hours.